IRX4204 Promotes Alpha-Synuclein Clearance in Parkinson's

Io Therapeutics, a privately held pharmaceutical company, announced on August 5, 2026, the presentation of new research demonstrating that its phase II clinical-stage RXR nuclear receptor agonist, IRX4204, promotes degradation of alpha-synuclein protein in human neural cells. The findings were presented at the International Retinoids Conference VIII in Niagara Falls, New York, by scientists from the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, part of Mass General Brigham. The research, led by Arunpati Tripathi and Ulf Dettmer, showed that RXR agonism stimulates the autophagy-lysosome pathway to clear accumulated alpha-synuclein in human cell models and patient-derived iPSC neurons. IRX4204 was found to be more potent than bexarotene, an FDA-approved drug. The company also highlighted IRX4204's favorable safety profile and prior clinical activity in Parkinson's disease, and plans future Phase IIb and Phase III trials to study its effects on disease progression.